FTC Approves Final Order Settling Charges That Watson Pharmaceuticals, Inc.'s Acquisition of Actavis Inc. Would Have Been Anticompetitive

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Watson Pharmaceuticals, Inc.’s proposed acquisition of Actavis Inc. would have been anticompetitive in the markets for 21 current and future generic drugs used to treat a wide range of conditions ranging from hypertension and diabetes to anxiety and attention deficit hyperactivity disorder (ADHD). The proposed order settling the agency’s charges required Watson and Actavis to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc and to relinquish the manufacturing and marketing rights to three other drugs.

The Commission vote approving the final order was 5-0. (FTC File No. 121-0132, Docket No. C-4373; the staff contact is Lisa De Marchi Sleigh, Bureau of Competition, 202-326-2535; see press release dated October 15, 2012)

The Federal Trade Commission works for consumers to prevent fraudulent, deceptive, and unfair business practices and to provide information to help spot, stop, and avoid them. To file a complaint in English or Spanish, visit the FTC's online Complaint Assistant or call 1-877-FTC-HELP (1-877-382-4357). The FTC enters complaints into Consumer Sentinel, a secure, online database available to more than 2,000 civil and criminal law enforcement agencies in the U.S. and abroad. The FTC’s website provides free information on a variety of consumer topics. Like the FTC on Facebook, follow us on Twitter, and subscribe to press releases for the latest FTC news and resources.